# Wave Life Sciences Inc. (WVE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.86, market value $958 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Wave Life Sciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 22.4×**. Each dollar of revenue is priced at 22.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -20.2%** (5-yr avg -19.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -504.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -478.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -39.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -32.0%**. Each dollar of assets produces -32.0% of profit.

## Growth
- **Revenue growth (1 yr): -60.5%** (3-yr 127.1%/yr, 5-yr 16.3%/yr). Revenue fell 60.5% over the last year, against 16.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -72.9%**. Earnings per share fell 72.9%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 6.47** (quick 6.47). Current assets cover the next year's liabilities 6.47 times.
- **Altman Z-score: 6.19**. A Z-score of 6.19 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Wave Life Sciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (16 analysts). 16 analysts cover Wave Life Sciences Inc.; the consensus is strong_buy, with an average price target of $19.06 (+292% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -40.6%** (YTD -71.4%, 3-mo -15.2%). The shares are down 40.6% over twelve months including dividends.
- **From 52-week high: -77.6%** (4.5% above the low). Trading 78% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 1.27** (volatility 168%). Beta of 1.27 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=WVE · Page: https://foliofundamentals.com/stocks/wve

Not investment advice.